ArticleCureus2025
Fondaparinux Failure in Heparin-Induced Thrombocytopenia With Acute Limb Ischemia: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT), a prothrombotic disorder caused by heparin-dependent antibodies, is often treated with fondaparinux, generally yielding positive outcomes. A 69-year-old male with a history of stage IIIb small cell lung cancer developed severe HIT (platelet count nadir, 11 × 10⁹/L) after receiving heparin for stroke prophylaxis, complicated by deep vein thrombosis (DVT) and acute limb ischemia (ALI). Despite treatment with fondaparinux, thrombocytopenia secondary to HIT persisted, and his arterial thrombosis progressed, leading to urgent angioplasty and thrombectomy. This clinical course raised concerns for autoimmune HIT (aHIT) refractory to fondaparinux or potential fondaparinux cross-reactivity. The patient was transitioned to argatroban postoperatively, resulting in rapid platelet recovery and clinical improvement. Our case highlights the limitations of fondaparinux in select HIT cases, particularly when aHIT is suspected, and underscores the need for vigilance in monitoring for treatment failure. This report adds to emerging data on alternative anticoagulation strategies for refractory HIT, including the potential role of direct thrombin inhibitors in severe cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.